Skip to main navigation
iTeos Therapeutics - Cancer Immunotherapies by Design iTeos Therapeutics - Cancer Immunotherapies by Design

Main Nav

  • Home
  • About us
    • Overview
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Pipeline
    • Pipeline
    • Clinical trials
    • A2A Receptor Antagonist
    • TIGIT antagonist monoclonal antibody
    • Preclinical pipeline
  • Technology
    • Cancer Immunotherapy & Immunosuppression
    • Scientific Publications
  • Investors
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Join the iTeos Team
  • Contact us

Main Nav

  • Home
  • About us
    • Overview
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Pipeline
    • Pipeline
    • Clinical trials
    • A2A Receptor Antagonist
    • TIGIT antagonist monoclonal antibody
    • Preclinical pipeline
  • Technology
    • Cancer Immunotherapy & Immunosuppression
    • Scientific Publications
  • Investors
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Join the iTeos Team
  • Contact us
Skip to main content

sub Governance

  • Management Team
  • Board of Directors
  • Documents & Charters
  • Committee Composition

Committee Composition

Committee Composition

Audit Committee Compensation Committee Nominating and Corporate Governance Committee
Priyanka Belawat Audit Committee
Detlev Biniszkiewicz
Derek DiRocco Audit Committee
David Hallal Nominating and Corporate Governance Committee
Ann Rhoads Audit Committee Compensation Committee Nominating and Corporate Governance Committee
Tim Van Hauwermeiren Compensation Committee Nominating and Corporate Governance Committee
= Chairperson = Member = Chairman of the Board = Financial Expert
© 2020 iTeos Therapeutics. iTeos, iTeos logo and Cancer Immunotherapies By Design are trademarks of iTeos Therapeutics Inc.

Socials

LinkedIn Twitter

Footer Nav

Privacy policy Terms of use